Literature DB >> 11434827

Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.

S M Cadarette1, S B Jaglal, T M Murray, W J McIsaac, L Joseph, J P Brown.   

Abstract

CONTEXT: Identification of women with low bone mineral density (BMD) is an important strategy in reducing the incidence of osteoporotic fractures. However, screening all women is not recommended.
OBJECTIVES: To assess the diagnostic properties of 4 decision rules--Simple Calculated Osteoporosis Risk Estimation (SCORE), Osteoporosis Risk Assessment Instrument (ORAI), Age, Body Size, No Estrogen (ABONE), and body weight less than 70 kg (weight criterion)--for selecting women for dual-energy x-ray absorptiometry (DXA) testing and to compare results with recommendations made in the National Osteoporosis Foundation (NOF) practice guidelines. DESIGN AND
SETTING: Analysis of data from the Canadian Multicentre Osteoporosis Study, a population-based community sample, collected from 9 study centers across Canada between February 1996 and September 1997. PARTICIPANTS: Postmenopausal women aged 45 years or older (N = 2365) without bone disease who had DXA data for the femoral neck, data to apply selection criteria, and who were not currently taking estrogens or who had been taking hormone replacement therapy for 5 or more years. MAIN OUTCOME MEASURES: Sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curve of each of the 4 decision rules and the NOF guidelines for identifying women with a BMD T score of less than -1.0 SD, less than -2.0 SD, and no more than -2.5 SD at the femoral neck, and percentages of women recommended for testing, stratified by BMD level and age.
RESULTS: The percent of women with a BMD T score less than -1, less than -2, and no more than -2.5 were 68.3%, 25.4%, and 10.0%, respectively. The AUROC curves were greatest using SCORE and ORAI. The sensitivity for identifying women with a BMD T score of less than -2.0 was 93.7% (95% confidence interval [CI], 91.8%-95.6%) using the NOF guidelines and was 97.5% (95% CI, 96.3%-98.8%), 94.2% (95% CI, 92.3%-96.1%), 79.1% (95% CI, 75.9%-82.3%), and 79.6% (95% CI, 76.4%-82.8%), respectively, using the SCORE, ORAI, ABONE, and weight criterion. However, the NOF guidelines also resulted in 74.4% (95% CI, 71.3%-77.6%) of women with a normal BMD (T score of -1.0 or higher) being tested compared with 69.2% (95% CI, 65.9%-72.5%), 56.3% (95% CI, 52.7%-59.8%), 35.8% (95% CI, 32.4%-39.2%), and 38.1% (95% CI, 34.6%-41.6%), respectively, using the 4 decision rules. Assessments suggest that ABONE and weight criterion are not useful case-finding approaches.
CONCLUSION: The SCORE and ORAI decision rules are better than the NOF guidelines at targeting BMD testing in high-risk patients. The acceptability of these rules in clinical practice merits further investigation given their potential effect on the use of densitometry services.

Entities:  

Mesh:

Year:  2001        PMID: 11434827     DOI: 10.1001/jama.286.1.57

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  45 in total

1.  Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Authors:  Smita Nayak; Mark S Roberts; Susan L Greenspan
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

2.  Dental panoramic radiograph as a tool to detect postmenopausal women with low bone mineral density: untrained general dental practitioners' diagnostic performance.

Authors:  Takashi Nakamoto; Akira Taguchi; Masahiko Ohtsuka; Yoshikazu Suei; Minoru Fujita; Keiji Tanimoto; Mikio Tsuda; Mitsuhiro Sanada; Koso Ohama; Junichiro Takahashi; Madeleine Rohlin
Journal:  Osteoporos Int       Date:  2003-06-24       Impact factor: 4.507

Review 3.  Prescreening tools to determine who needs DXA.

Authors:  Elliott N Schwartz; Dee M Steinberg
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

4.  Use of dental panoramic radiographs in identifying younger postmenopausal women with osteoporosis.

Authors:  Akira Taguchi; Mikio Tsuda; Masahiko Ohtsuka; Ichiro Kodama; Mitsuhiro Sanada; Takashi Nakamoto; Koji Inagaki; Toshihide Noguchi; Yoshiki Kudo; Yoshikazu Suei; Keiji Tanimoto; Anne-Marie Bollen
Journal:  Osteoporos Int       Date:  2005-12-06       Impact factor: 4.507

5.  Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry.

Authors:  B Rud; J E B Jensen; L Mosekilde; S P Nielsen; J Hilden; B Abrahamsen
Journal:  Osteoporos Int       Date:  2004-09-30       Impact factor: 4.507

6.  Canadian Consensus Conference on osteoporosis, 2006 update.

Authors:  Jacques P Brown; Michel Fortier; Heather Frame; André Lalonde; Alexandra Papaioannou; Vyta Senikas; Chui Kin Yuen
Journal:  J Obstet Gynaecol Can       Date:  2006-02

Review 7.  Performance of the Osteoporosis Self-Assessment Tool in ruling out low bone mineral density in postmenopausal women: a systematic review.

Authors:  B Rud; J Hilden; L Hyldstrup; A Hróbjartsson
Journal:  Osteoporos Int       Date:  2007-03-15       Impact factor: 4.507

Review 8.  Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature.

Authors:  E J Waugh; M-A Lam; G A Hawker; J McGowan; A Papaioannou; A M Cheung; A B Hodsman; W D Leslie; K Siminoski; S A Jamal
Journal:  Osteoporos Int       Date:  2008-06-04       Impact factor: 4.507

Review 9.  Clinical guidelines for the application of panoramic radiographs in screening for osteoporosis.

Authors:  Akira Taguchi; Ray Tanaka; Naoya Kakimoto; Yasuhiro Morimoto; Yoshinori Arai; Takafumi Hayashi; Tohru Kurabayashi; Akitoshi Katsumata; Junichi Asaumi
Journal:  Oral Radiol       Date:  2021-02-23       Impact factor: 1.852

10.  Artificial neural networks in prediction of bone density among post-menopausal women.

Authors:  M Sadatsafavi; A Moayyeri; A Soltani; B Larijani; M Nouraie; S Akhondzadeh
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.